Greenwich LifeSciences (GLSI) Stock Price, News & Analysis

Company Overview

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Key Stats

• Today's Range: $10.70 to $11.29
• 50-Day Range: $8.76 to $12.30
• 52-Week Range: $8.06 to $16.50
• Volume: 45,636 shs
• Average Volume: 77,471 shs
• Market Capitalization: $148.27 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $39.00
• Consensus Rating: Buy

Greenwich LifeSciences Stock Analysis - MarketRank™

Greenwich LifeSciences scored higher than 27% of companies evaluated by MarketBeat, and ranked 806th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Greenwich LifeSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Greenwich LifeSciences has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Greenwich LifeSciences are expected to decrease in the coming year, from ($0.80) to ($0.81) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Greenwich LifeSciences is -8.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Greenwich LifeSciences is -8.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Greenwich LifeSciences has a P/B Ratio of 58.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.69% of the float of Greenwich LifeSciences has been sold short.

Short Interest Ratio / Days to Cover

Greenwich LifeSciences has a short interest ratio ("days to cover") of 17.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Greenwich LifeSciences has recently decreased by 2.91%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Greenwich LifeSciences does not currently pay a dividend.

Dividend Growth

Greenwich LifeSciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

16.69% of the float of Greenwich LifeSciences has been sold short.

Short Interest Ratio / Days to Cover

Greenwich LifeSciences has a short interest ratio ("days to cover") of 17.5, which indicates bearish sentiment.

Change versus previous month

Short interest in Greenwich LifeSciences has recently decreased by 2.91%, indicating that investor sentiment is improving.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

3 people have searched for GLSI on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Greenwich LifeSciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

51.67% of the stock of Greenwich LifeSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 4.16% of the stock of Greenwich LifeSciences is held by institutions.

GLSI Stock Analysis - Frequently Asked Questions

How have GLSI shares performed this year?

Greenwich LifeSciences' stock was trading at $11.23 at the beginning of 2025. Since then, GLSI stock has decreased by 1.2% and is now trading at $11.09.

How were Greenwich LifeSciences' earnings last quarter?

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) posted its earnings results on Tuesday, May, 20th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.24) by $0.01.

When did Greenwich LifeSciences IPO?

Greenwich LifeSciences (GLSI) raised $7 million in an IPO on Friday, September 25th 2020. The company issued 1,300,000 shares at $5.75 per share. Aegis Capital served as the underwriter for the IPO.

How do I buy shares of Greenwich LifeSciences?

Shares of GLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Greenwich LifeSciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Greenwich LifeSciences investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 5/20/2025
• Today: 8/02/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GLSI
• CIK: 1799788
• Web: www.greenwichlifesciences.com
• Phone: 832-819-3232
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Greenwich LifeSciences: $39.00
• High Price Target: $39.00
• Low Price Target: $39.00
• Potential Upside/Downside: +251.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.79 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -450.87%
• Return on Assets: -333.18%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.91
• Quick Ratio: 1.91

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.19 per share
• Price / Book: 58.37

Miscellaneous

• Outstanding Shares: 13,370,000
• Free Float: 6,461,000
• Market Cap: $148.27 million
• Optionable: Not Optionable
• Beta: 1.65